KRRO

Korro BioF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$18.00

+63.6% vs current

Most likely

Base case

45%

Probability

Target price

$14.00

+27.3% vs current

B-

Bear case

30%

Probability

Target price

$8.00

-27.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This remains a cautious post-earnings monitoring setup rather than a clean thesis upgrade. The company-source evidence on May 7, 2026 improved balance-sheet visibility and preserved the Q2 2026 AATD nomination, 2H 2026 KRRO-121 filing, and 2H 2026 third GalNAc-conjugated program nomination milestones, but no trustworthy checked source provided a clear consensus surprise or meaningful T+3 analyst-revision signal. The added long-horizon program catalyst helps round out the milestone map, but it is still preclinical optionality and does not remove the low-coverage, high-uncertainty profile.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-05-31catalystQ1 earnings reset extends runway but looks partly absorbedMedium impact

Korro's May 7, 2026 earnings update reaffirmed cash, cash equivalents and marketable securities of $157.1 million at March 31, 2026 and management said that should fund operations into the second half of 2028, helped by the oversubscribed $85 million private placement; that lowers near-term financing pressure, but the liquidity benefit is likely partly reflected already [#8-K-2026-05-07][#10-Q-2026-05-07].

2026-06-30eventGalNAc AATD development-candidate nomination remains the nearest clean proof pointHigh impact

Management said it is on track to announce a development candidate for the GalNAc-conjugated AATD program in the second quarter of 2026 after reporting greater than 90% in vivo RNA editing, making this the nearest execution checkpoint for whether the post-KRRO-110 pivot is translating into a credible follow-on asset [#8-K-2026-05-07].

2026-10-15eventKRRO-121 regulatory filing in 2H 2026 is still the main value inflectionHigh impact

The company reiterated that KRRO-121 remains on track for a regulatory filing in the second half of 2026 to enable a first-in-human trial, which remains the core asset-specific catalyst because Korro is still pre-revenue and heavily dependent on converting preclinical work into a clinical program [#10-Q-2026-05-07][#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology